Partner with Us
Life Edit uses its proprietary gene editing platform to develop new editing compositions, to research editing at novel genomic loci, and develop therapeutic assets. We are looking to form strategic partnerships with biotechnology and biopharmaceutical companies to advance their life-changing and curative therapies.
Our flexible partnership options include broad R&D collaborations, exclusive and non-exclusive licenses for specific assets, and strategic partnerships to access our technology platforms designed to accelerate the pipelines of our partners.
Our Technology Platform
Our gene editing platform offers one of the world’s largest and most diverse collections of novel RNA-guided nucleases (RGNs) base editors, and reverse transcriptase (RT) editors, that provide flexible editing, both in vivo and ex vivo, and unprecedented access to the genome. Our gene editing systems are available to license non-exclusively for enablement of ex vivo cell therapies as well as exclusively through R&D collaborations for in vivo therapeutic development.
Capabilities
Our gene editing tools, first developed using a proprietary collection of non-pathogenic microbes, are continually being improved and expanded through new discovery and engineering powered by artificial intelligence.
Novel RGNs
Large and diverse library of RNA-guided nucleases including Type II and Type V systems that encompass knock-out and knock-in capabilities, transcriptional regulation, and base editing when coupled with one of our proprietary deaminases, as well as next-generation gene editing platform.
Base Editors
Several classes of DNA modifying enzymes, including novel deaminases for cytidine (C) or adenine (A) base editing.
Base editing converts one nucleotide base into another, without cutting both strands of DNA. This is achieved by coupling a nuclease, modified to cut only one DNA strand, to a deaminase that edits the target nucleotide. Our modular approach to base editing couples our proprietary nucleases and deaminases to one another.
RT Editors
Reverse transcriptase (RT) editing, also known as prime editing, involves cutting one DNA strand, then replacing, adding to, or deleting a genomic sequence with a new sequence that is encoded by the guide RNA (gRNA).
Our approach takes advantage of our panel of RGNs to enable optimal editing of the target locus.
In vivo Delivery
Many of our RGNs are smaller than widely used CRISPR-Cas systems, offering ease and flexibility for in vivo delivery.
Ex vivo Engineering
Our platform enables ex vivo engineering for cell therapies and regenerative medicines.
Broad Range of PAMS
Our nuclease collection has a broad range of Protospacer Adjacent Motifs (PAMs) which offer unprecedented access to genomes.
Artificial Intelligence to Accelerate CRISPR Discovery and Design
Harnessing the power of artificial intelligence (AI), we propel CRISPR discovery and engineering efforts at an unprecedented pace to enable the development of promising therapeutic options for the broadest range of genetic disorders and diseases that were once deemed untreatable. To achieve this, we believe we have to look beyond nature-derived CRISPR systems to the design of synthetic CRISPRs that can be tailored for each disease. We believe leveraging AI will accelerate the path towards this goal.
Partnership Spotlights
In 2023, we formalized two groundbreaking R&D collaborations – one with Moderna and another with Novo Nordisk – to apply our Life Edit platform for the development of in vivo mRNA gene editing therapies and base editing therapies.
Moderna
Life Edit Therapeutics, an ElevateBio company, formed an R&D collaboration with Moderna Therapeutics to discover and develop in vivo mRNA gene editing therapies, combining the platform technologies of both organizations.
Novo Nordisk
Life Edit Therapeutics, an ElevateBio company, formed a strategic collaboration with Novo Nordisk to discover, develop, and deliver base editing therapies for rare and cardiometabolic diseases. Novo Nordisk will leverage Life Edit’s suite of gene editing technologies to precisely edit the genome with the aim of developing life-changing therapies.
Our ElevateBio Ecosystem
ElevateBio’s integrated ecosystem combines R&D platforms – including Life Edit gene editing – with cGMP manufacturing at BaseCamp®. This synergy bridges the gap between discovery and the widespread delivery of therapies as everyday medicine. By leveraging advanced technologies, we unlock scientific advancements and translate them into scalable manufacturing processes, creating meaningful therapeutic developments.
Partner with Life Edit
